Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
December 13th 2022“One of the things that drives me to be a part of advanced prostate cancer care is that literally every 6 months, we are having major trials read out guideline-based changes in care,” says Jason Hafron, MD.
A Look Into The Future of PSMA-Targeted Therapies in Prostate Cancer
December 12th 2022Panelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.
Darolutamide now available in England for mHSPC
November 29th 2022Approval of the treatment was based on the placebo-controlled phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT and docetaxel boosted overall survival versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Concurrent/adjuvant ADT sequencing appears optimal in patients receiving prostate-only RT
November 22nd 2022“To our knowledge, this study represents the first time a significant association has been demonstrated between concurrent and adjuvant ADT sequencing and overall survival rates among prostate cancer patients," says Amar Kishan, MD.
Sequencing of Conventional and PSMA-PET Imaging in Prostate Cancer
November 21st 2022Citing recent guidelines recommendations, urologists share how they approach sequencing of conventional and PSMA-PET imaging for patients with prostate cancer, and discuss how use of each modality might affect subsequent patient management and treatment decisions.
Incorporating Newer Imaging Modalities Into Clinical Practice and Considerations for Nomenclature
November 14th 2022Panelists consider how they have incorporated some newer imaging modalities, including PSMA-PET, into their clinical practice, and discuss the terminology that urologists and radiologists have recently used to describe these modalities.
Dr. Goldberg explains disparities in shared decision-making for prostate cancer screening
November 7th 2022“We do know that for these specific racial minorities, more time and more tools need to be invested in order to have both the rates of PSA discussion and PSA testing equal to those that White men have,” says Hanan Goldberg, MD, MSc.
Patient Risk Stratification and Evolving Imaging Modalities in Prostate Cancer
November 7th 2022Expert panelists review risk stratification strategies for patients with prostate cancer and summarize the evolving use of conventional versus newer imaging modalities for diagnosis, treatment selection, and monitoring of these patients.
Yale professors create new drug that could combat prostate cancer
October 12th 2022A Yale chemist and oncologist collaborated to create a new treatment for prostate cancer that tags specific proteins within the cancerous cells, making it easier for the body’s natural mechanisms to identify and destroy them.